DexCom (DXCM) Stock Price Target 2026

The average analyst price target for DexCom is $92.27, 15.1% above the current price. Of 26 analysts, 24 rate it Buy and 2 Hold. Targets range from $64 to $120. The latest change came on Oct 30, 2026, when UBS raised its price target on DexCom from $102 to $107 and kept a Buy rating.

The Average Analyst Price Target for DexCom is $92.27.

Price Target Range — 9 Quarters

Analyst Consensus — 26 Analysts

1S.Buy

23Buy

2Hold

Consensus RatingBuy# Analysts26Avg. Consensus PT$92.27Upside to Avg. PT+15.1%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for DexCom Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	UBS	Patrick Wood	PT Raise	Buy	$102→$107
Oct 30, 2026	Canaccord Genuity	William Plovanic	PT Raise	Buy	$90→$97
Oct 30, 2026	JP Morgan	Robbie Marcus	PT Raise	Neutral	$82→$85
Oct 30, 2026	Barclays	Christopher Pasquale	PT Raise	Overweight	$115→$120
Oct 30, 2026	StoneX	Bruce D. Jackson	PT Raise	Buy	$82→$93
Oct 12, 2026	BTIG	Ryan Zimmerman	PT Raise	Buy	$90→$96
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Overweight	$115
Oct 1, 2026	RBC Capital	Kendall Au	PT Raise	Outperform	$90→$105
Sep 18, 2026	Truist Securities	Richard Newitter	PT Raise	Buy	$93→$102
Sep 18, 2026	TD Cowen	Joshua Jennings	Maintained	Buy	$95
Aug 4, 2026	Argus Research	Steve Silver	PT Raise	Buy	$86→$96
Aug 3, 2026	Canaccord Genuity	William Plovanic	PT Raise	Buy	$82→$90
Jul 31, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$84→$88
Jul 31, 2026	RBC Capital	Kendall Au	PT Raise	Outperform	$85→$90
Jul 31, 2026	Mizuho	Anthony Petrone	PT Raise	Outperform	$90→$95
Jul 31, 2026	JP Morgan	Robbie Marcus	PT Raise	Neutral	$65→$82
Jul 31, 2026	Piper Sandler	Matt O'Brien	PT Raise	Overweight	$88→$95
Jul 31, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$85→$90
Jul 31, 2026	Stifel	Jonathan Block	PT Raise	Buy	$90→$95
Jul 31, 2026	Benchmark	Bruce D. Jackson	PT Raise	Buy	$77→$82